Form 4: Apellis CEO Cedric Francois Granted 195,952 RSUs

Apellis Pharmaceuticals CEO Cedric Francois received a grant of 195,952 Restricted Stock Units, vesting over four years.

Summary

• Cedric Francois, CEO and Director of Apellis Pharmaceuticals, Inc. (APLS), was granted 195,952 shares of Common Stock.
• This grant represents a Restricted Stock Unit (RSU) award with a transaction date of January 28, 2026.
• The RSUs will vest 25% annually over four years, contingent on continued service.
• Following this transaction, Cedric Francois directly beneficially owns 481,997 shares of Common Stock.
• Additionally, he indirectly beneficially owns 1,314,422 shares through various trusts, bringing his total beneficial ownership to 1,796,419 shares.
• The indirect holdings include shares held by The Cedric Francois Irrevocable Trust of 2023 2 (307,946 shares), The Cedric Francois Irrevocable Trust of 2023 (472,065 shares), The Francois Grossi Trust (300,000 shares), and The Francois-DuBois Educational Trust (234,411 shares).
• Cedric Francois disclaims beneficial ownership over the shares held by these trusts except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard executive incentive aligning management's long-term interests with shareholders, without indicating any immediate operational changes or financial distress.

Positives

• The grant of 195,952 Restricted Stock Units (RSUs) aligns the CEO's incentives with long-term shareholder value creation.
• The four-year vesting schedule encourages continued leadership and commitment to the company's strategic objectives.

Negatives

• No immediate negative implications are apparent from this routine RSU grant.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The Restricted Stock Unit award granted on January 28, 2026, is structured to vest 25% annually over four years from the grant date, contingent upon Cedric Francois's continued service to the company. This indicates a planned long-term incentive structure for the CEO.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that RSU grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to retain key talent and align management interests with long-term company performance. This grant to Apellis's CEO is consistent with typical practices for incentivizing leadership in a growth-oriented biotech firm.

Comparison to Industry Standards

• The RSU grant to Cedric Francois is a common form of equity compensation for CEOs in the biotechnology sector, comparable to practices at companies like Moderna, BioNTech, or Regeneron, which frequently use multi-year vesting schedules to ensure executive retention and long-term commitment.
• The vesting schedule of 25% annually over four years is a standard industry practice for executive equity awards, similar to those observed at peer companies in the pharmaceutical and biotech space.

Related Party Transactions

• The filing discloses shares held indirectly by various trusts (The Cedric Francois Irrevocable Trust of 2023 2, The Cedric Francois Irrevocable Trust of 2023, The Francois Grossi Trust, and The Francois-DuBois Educational Trust), for which Cedric Francois disclaims beneficial ownership except to the extent of his pecuniary interest. These trusts are considered related parties due to their connection to the reporting person.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's long-term interests with shareholder value creation, potentially fostering stability and strategic focus.
• Employees: The grant to the CEO may signal confidence in the company's future, potentially boosting morale.
• Management: The equity award serves as a significant incentive for the CEO's continued leadership and performance.

Next Steps

• The granted Restricted Stock Units will vest 25% annually over the next four years, subject to Cedric Francois's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine RSU grant to the CEO, which is a standard compensation practice and does not provide new information that would fundamentally alter the investment thesis for Apellis Pharmaceuticals. It reinforces management's long-term alignment but offers no immediate catalysts for a 'buy' or 'sell' decision, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Cedric Francois, Restricted Stock Units, RSU grant, insider transaction, beneficial ownership, CEO compensation, equity award